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Byung-Sik Cho,1 Chang-Ki Min,1 Hee-Je Kim,1 Seok Lee,1 Yoo-Jin Kim,1 Ji-Young Lim,1
Dae-Chul Jeong,2 Bin Cho,2 Hack-Ki Kim,2 Ki-Seong Eom,1 Seok-Goo Cho,1
Dong-Wook Kim,1 Jong-Wook Lee,1 Woo-Sung Min,1 Chun-Choo Kim,1 Nak-Gyun Chung2B cell activating factor (BAFF), also known as B cell survival and activation factor, is associated with autoim-
mune disease and chronic graft-versus-host disease (cGVHD). T cells are known to be modulated by soluble
BAFF (sBAFF). Considering the possible association of sBAFF with T cell as well as B cell function, sBAFF
during the peritransplantation period may affect the development of acute GVHD (aGVHD). To test this hy-
pothesis, we evaluated 45 patients who had undergone myeloablative (MA) allogeneic stem cell transplanta-
tion (SCT) for hematologic malignancy. Serum sBAFF levels were measured before conditioning and on day 0,
day 17, and day 114. Thirty-three of the 45 patients (cumulative incidence, 73%) developed aGVHD be-
tween 16 days and 98 days posttransplantation. Repeated-measures analysis of variance revealed significantly
lower sBAFF levels during the peritransplantation period in patients with aGVHD than in those without
aGVHD (P5.001). Receiver operating characteristic curve analysis revealed that sBAFF levels at every
time point were available for the prediction of aGVHD development, and that patients with a sBAFF level
.43 pg/mL at each time point (which could ensure 75% sensitivity and 73%-82% specificity for the prediction
of aGVHD at every time point) had a significantly lower cumulative incidence of aGVHD. This study is the
first to demonstrate that sBAFF level during the peritransplantation period not only may be predictive of
aGVHD, but also may have a protective effect against aGVHD in humans. Further investigation is needed
to confirm our findings.
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cause of mortality after allogeneic stem cell transplan-
tation (SCT). Human leukocyte antigen (HLA) differ-
ences between donor and recipient are the major
predictors of GVHD [1]. Other implicated factors
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6/j.bbmt.2009.11.023[2], mismatched minor histocompatibility antigens
(mHA) in otherwise identical SCT [3], donor age [4],
stem cell source and dose [5], intensity of conditioning,
and GVHD prophylaxis [6]. Numerous trials have
been conducted in an effort to find other predictors
of acute GVHD (aGVHD) using non–HLA-depen-
dent factors, such as polymorphisms of the cytokine
gene (NOD2, CARD15), genes influencing the phar-
macokinetics of widely used immunosuppressive
drugs, and gene expression profiles of CD41 and
CD81 T cells from donors [7].
B cell activating factor (BAFF) was recently identi-
fied as a critical regulator of normal B cell homeostasis
in mice and humans [8,9]. The known major function
of soluble BAFF (sBAFF) is an essential B cell survival
and activation factor, which when overexpressed can
affect B cell tolerance [8-10]. sBAFF is required for
the reconstitution of B cells after myeloablation in an-
imal models [11]. High sBAFF levels have been629
Table 1. Patient Characteristics
Characteristic Overall (n5 45)
Patient age, years, median (range) 30 (16-51)
Donor age, years, median (range) 27 (13-55)
Patient sex, male/female, n (%) 25 (56)/20 (44)
Donor sex, male/female, n (%) 28 (62)/17 (38)
Sex match, match/mismatch, n (%) 22 (49)/23 (51)
Female to male, yes/no, n (%) 30 (67)/15 (33)
ABO type, match/mismatch, n (%) 17 (38)/28 (62)
Disease type, n (%)
AML 22 (49)
ALL 20 (44)
CML 3 (7)
Disease status, standard/advanced, n (%) 35 (78)/10 (22)
Donor type, sibling/unrelated, n (%) 22 (49)/23 (51)
HLA match/mismatch, n (%) 37 (82)/8 (18)
Stem cell source, bone marrow/
peripheral blood, n (%)
29 (64)/16 (36)
TBI or non-TBI, TBI/non-TBI, n (%) 40 (89)/5 (11)
GVHD prophylaxis, n (%)
CsA +MTX 20 (44)
Tacrolimus + MTX 25 (56)
Infused cells, mean (SE)
Mononuclear cells (108/kg) 5.4 (1.1)
CD34+ cells (106/kg) 4.7 (0.5)
CD3+ cells (107/kg) 18.3 (3.1)
AML indicates acute myelogenous leukemia; ALL, acute lymphoblastic
leukemia; CML, chronic myelogenous leukemia; TBI, total body irradia-
tion; CsA, cyclosporine A; GVHD, graft-versus-host disease; MTX,
methotrexate.
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eases [12-15], suggesting that excessive sBAFF stimu-
lation in humans contributes to the development of
autoimmunity. In addition to the fact that the clinical
features of chronic GVHD (cGVHD) are similar to
those of autoimmune diseases [16], mounting evi-
dence, including the correlation between cGVHD
and antibodies to Y chromosome–encoded mHA gen-
erated after sex-mismatched allogeneic SCT [17] and
the clinical response of steroid-refractory cGVHD
by rituximab [18], implicates B cells in the pathophys-
iology of cGVHD. Notably, recent human studies
demonstrating the association between high sBAFF
level and cGVHD also support the notion that B cells
play a role in the development of cGVHD [19-21].
The role of B cells in the development of aGVHD
is uncertain. Recent studies have suggested a possible
role of B cells in the development of aGVHD by dem-
onstrating the association between B cell depletion in
the recipient [22] or graft [23] and reduced incidence
of aGVHD. T cells play a pivotal role in the develop-
ment of aGVHD [24] and are modulated by sBAFF
[25-28]. Considering the role of sBAFF in the modula-
tion of both T and B cells, sBAFF level during the peri-
transplantation period may have an effect on the
development of aGVHD. However, there have been
no reports regarding early changes in sBAFF level after
SCT (within 1 month), or on an association between
sBAFF level and aGVHD. To test this hypothesis,
we assessed the changes in sBAFF level during the
peritransplantation period in a group of patients who
underwent myeloablative (MA) allogeneic SCT.METHODS
Patient and Transplant Characteristics
This study examined 45 consecutive patients who un-
derwent allogeneic SCT for hematologic malignancies at
the Catholic Blood and Marrow Transplantation Center
between January and September 2008. Patient characteris-
tics are summarized in Table 1. Only patients with hema-
tologic malignancies were included in the study; the cohort
included 22 patients with acute myelogenous myeloid leu-
kemia (AML), 20 with acute lymphoblastic leukemia
(ALL), and 3 with chronic myelogenous leukemia
(CML). No patient with ALL received a steroid medica-
tion (except during induction chemotherapy) or rituximab
before transplantation [29]. Of the 45 patients examined,
22 received a transplant from a related donor and 23 re-
ceived a transplant from an unrelated donor. Patients
were defined as being in advanced disease status at trans-
plantation if they had either AML or ALL in any state
other than first complete remission (CR1) or CML in
anystateother thanfirst chronicphase (CP1).Allotherpa-
tients were classified as having standard disease status.All patients received an MA conditioning regimen
consisting of total body irradiation (TBI) 1320 cGy/
cyclophosphamide (Cy), TBI 1200 cGy/CY, busulfan
(Bu)/CY, or TBI 1200 cGy/cytarabine/melphalan
(Mel). Overall, 29 patients received bone marrow
(BM) stem cells and 16 received granulocyte colony-
stimulating factor (G-CSF)-mobilized peripheral
blood stem cells (PBSCs). HLA matching was con-
ducted based on high-resolution genotyping for both
HLA class I (HLA-A, -B, -C) and II (HLA-DRB1) an-
tigens. Thirty-seven of the 45 patients (82%) received
a transplant from a fully matched HLA donor, and the
others received a transplant from a donor with at least
one HLA allele/antigen mismatch (1 allele, n5 2; 2 al-
leles, n5 2; 1 antigen, n5 4). G-CSF was adminis-
tered to all patients at a dose of 5 mg/kg per day s.c.
from day 17 until neutrophil recovery. On day 21
posttransplantation, chimerism of donor and recipient
cells in peripheral blood for 16 human-specific gene
probes was assessed by multiplex fluorescent short tan-
dem repeat analysis (multiple and automated fragment
analyzer-based typing; Applied Biosystems, Foster
City, CA). The other general transplantation proce-
dures were conducted as described previously
[30,31]. The median follow-up time for this cohort,
calculated as the time from the transplantation to the
final collection, was 200 days (range, 45-360 days).GVHD Prophylaxis and Treatment
For GVHD prophylaxis, 20 patients (44%) re-
ceived a combination of cyclosporine (CsA) and
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tered i.v. as a continuous infusion at a dose of 3 mg/
kg from days21 to121, and then 5 mg/kg/day divided
into 2 doses thereafter, to maintain a blood concentra-
tion of 200-400 ng/mL. MTX was administered at
a dosage of 10 mg/m2 on days 11, 13, 16, and 111.
Twenty-five patients (56%) received GVHD prophy-
laxis with tacrolimus and MTX. Tacrolimus was ad-
ministered i.v. as a continuous infusion at a dose of
0.03 mg/kg from days 21 to 121, and then orally at
a total dose of 0.12 mg/kg/day, divided into 2 doses,
to maintain a blood concentration of 10-20 ng/mL
[32]. Antithymocyte globulin (ATG; IMTIX-Sangstat,
Lyon, France), 1.25 mg/kg once daily on days23 to -2,
was administered to 13 patients who had received unre-
lated PBSCs or a transplant from an allele/antigen-
mismatched unrelated donor [33]. Diagnoses of
aGVHD and cGVHD were made by consensus criteria
as described previously [16,34]. aGVHD was defined as
GVHD occurring within 100 days after transplanta-
tion. Methylprednisolone was administered at 2-
4 mg/kg/day for 4-7 days, with a gradual taper to treat
aGVHD of grade$II. Skin, rectum, stomach, or duo-
denum biopsy specimens were obtained when indi-
cated to confirm the diagnosis of GVHD.
Definitions of Other Complications
Fever was defined as a body temperature of
$38.3C for at least 2 consecutive days. A clinically
defined infection (CDI) was identified if the fever
was accompanied by the appropriate clinical findings,
including pulmonary infiltration or skin or soft tissue
inflammation [35]. Thrombotic microangiopathy
(TMA) was defined as described previously [36]. Cyto-
megalovirus (CMV) antigenemia was diagnosed by
polymerase chain reaction, and CMV DNA load-
guided, risk-adapted preemptive therapy was provided
to prevent CMV disease [37].
Blood Sample Collection and sBAFF Level
Determination
Blood samples for sBAFF measurement were col-
lected on the day immediately before conditioning
(preconditioning), on day 0 (before stem cell infusion),
and on days17 and114 posttransplantation, with the
patient’s fully informed consent. Venous blood (8 cc)
was drawn and placed in a serum separation tube
(Greiner Bio-One, Kremsmu¨nster, Austria) containing
coagulation activator. After 15 minutes of coagulation,
serum was separated from whole blood cells via 10 min-
utes of centrifugation at 2500 rpm. Serum above the gel
was stored in aliquots at280C and used after the first
thaw for sBAFF measurements. sBAFF levels in patient
serum samples were measured by commercially avail-
able enzyme-linked immunosorbent assay (ELISA) fol-
lowing the manufacturer’s recommended procedures(R&D Systems, Minneapolis, MN). Each sample was
tested in duplicate, and the average value is reported
as picograms per milliliter (pg/mL). The sensitivity of
detection ranged from 1 to 1000 pg/mL.Statistical Methods
The primary endpoint of this study was to charac-
terize the association of sBAFF level with aGVHD.
To assess the changes in sBAFF level during the peri-
transplantation period (preconditioning, day 0, day
17, and day 114) according to the development of
aGVHD, we assessed the course of each of the serum
levels from the date of preconditioning to the second
week after transplantation using both Mann-Whitney
tests and repeated-measures analysis of variance (AN-
OVA). Based on these findings, we performed a receiver
operating characteristic (ROC) curve analysis at each
time point to determine the availability and optimal cut-
off values of sBAFF level for predicting the occurrence
of aGVHD. Using an ROC curve, we determined the
identical cutoff value of sBAFF level at each time point
as 43 pg/mL, which could ensure 75% sensitivity and
73%-82% specificity for the prediction of aGVHD.
To assess the predictive role of sBAFF at each sam-
pling time for the development of aGVHD, we divided
the patients into 2 groups, high sBAFF (.43 pg/mL)
and low sBAFF (#43 pg/mL) at each time point based
on the cutoff sBAFF level determined by ROC curve
analysis. The incidence of aGVHD was calculated
and plotted using cumulative incidence estimates and
compared using the Gray test [38]. Multivariate analy-
ses including potential risk factors for aGVHD as vari-
ables were performed to explore the predictive role of
sBAFF levels or sBAFF groups by ROC curve analysis
on the occurrence of aGVHD on the basis of a semi-
parametric model for cumulative incidence [38]. The
associations of sBAFF levels with pretransplantation
factors or other transplantation outcomes including
neutrophil and platelet recovery, CDI, hemorrhagic
cystitis, TMA, and CMV infection, were evaluated as
well. The Mann-Whitney test was used to compare
the continuous variables. The association between
the categorical variables was assessed using either the
c2 test or Fisher’s exact test. Correlation analyses
were performed using Spearman’s (nonparametric)
analysis. All statistical analyses were conducted using
SPSS 13.0 (SPSS Inc, Chicago, IL), with the exception
of the cumulative incidence analysis, which was done
using R (freely available at http://www.r-project.org/).RESULTS
Transplantation Outcomes
All patients achieved engraftment. The median
time for neutrophil count to reach 0.5 109/L for 3
Figure 1. Serum sBAFF levels during the peritransplantation period.
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median time for platelet count to reach .20 109/L
without platelet transfusion was 19 days (range, 5-36
days). The median percentage of donor cells at day
21 was 99.3% (range, 94.3%-99.9%) Thirty-three of
the 45 patients developed aGVHD between 16 days
and 98 days after transplantation (median onset, 24
days). Overall, the cumulative incidence of aGVHD
was 73.3% (grade I, n5 6; grade II, n5 22; grade
III, n5 4; grade IV, n5 1). Eighteen of the evaluable
38 patients developed cGVHD; 10 with a limited
type and 8 with an extensive type. The cumulative in-
cidences of the posttransplantation CDI, hemorrhagic
cystitis, TMA, and CMV infection during the follow-
up period were 28.9%, 15.6%, 6.7%, and 24.4%,
respectively.
sBAFF Level and Transplantation Outcomes
sBAFF level was measured before conditioning
and on day 0, day 17, and day 114. The serial mea-
surements demonstrated decreased sBAFF levels after
conditioning, with the lowest level at day 0 and a grad-
ual increase after transplantation (Figure 1). We noted
a significant difference in the sBAFF level from pre-
conditioning to day 114 according to the occurrence
of aGVHD (Figure 2), whereas other posttransplanta-
tion complications were not associated with the sBAFF
level at every time point. No transplant characteristic
was associated with sBAFF level at each time point, ex-
cept for a trend toward a higher sBAFF level at day
114 in patients who received an unrelated transplant
(P5 .056) and those who received tacrolimus1MTX
for GVHD prophylaxis (P5 .055) (Table 2).
Repeated-measures ANOVA also showed that patients
with aGVHD had lower sBAFF levels during the peri-
transplantation period (P5 .001), but no other
transplant characteristic or clinical outcome was asso-
ciated with sBAFF level.
Analysis of Factors Predicting theOccurrence of
aGVHD
To determine other predictive factors associated
with the cumulative incidence of aGVHD, we assessed
several factors likely to have some influence on the de-
velopment of aGVHD via cumulative incidence esti-
mates. These factors included the age and sex of both
the patient and donor, diagnosis, donor–recipient sex
match, ABO match, disease status at transplantation,
HLA match, donor type, stem cell source, TBI-
containing or non–TBI-containing conditioning regi-
men, and type of GVHD prophylaxis. None of these
factors was significantly associated with the cumulative
incidence of aGVHD in this cohort (Table 3).
Multivariate analysis adjusted with the foregoing po-
tential risk factors for aGVHD revealed a significant as-
sociation between sBAFF level at each time point (as
a continuous variable) and the occurrence of aGVHD(preconditioning: relative risk [RR]5 1.022, 95%
confidence interval [CI]5 1.002-1.042, P5 .032; day
0: RR5 1.048, 95% CI5 1.015-1.082, P5 .004; day
17: RR5 1.032, 95% CI5 1.005-1.060, P5 .018; day
114: RR5 1.020, 95% CI5 1.001-1.048, P5 .040).
Predictive Role of sBAFF Level at Each Time
Point for aGVHD
Based on results of the association between sBAFF
level and aGVHD, we performed an ROC curve anal-
ysis to evaluate the availability of sBAFF level at each
time point for predicting the occurrence of aGVHD.
Figure 3 shows that sBAFF levels at every time point
were available for the prediction of aGVHD. Using
ROC curve analysis, the cutoff value of 43 pg/mL
that divides patients into 2 groups, high sBAFF
(.43 pg/mL) and low sBAFF (#43 pg/mL), was de-
termined. This value could ensure 75% sensitivity
and 73%-82% specificity for the prediction of
aGVHD at every time point. An analysis of the cumu-
lative incidence of aGVHD at each time point by
sBAFF group revealed that sBAFF level at every time
point is significantly predictive of the occurrence of
aGVHD (Figure 4). No transplant characteristic was
associated with sBAFF group (high or low) at every
time point (Table 4).
Multivariate analysis adjusted with the aforemen-
tioned potential risk factors for aGVHD revealed a sig-
nificant association between sBAFF group at each time
point (high vs low) and the occurrence of aGVHD (pre-
conditioning: RR5 6.3, 95% CI5 1.3-30.0, P5 .022;
day 0: RR5 10.2, 95% CI5 2.2-47.9, P5 .003; day
17: RR5 13.5, 95% CI5 2.8-65.4, P5 .001; day
114: RR5 9.4, 95% CI5 2.0-43.3, P5 .004).DISCUSSION
This study focused on an association between
sBAFF level during the peritransplantation period
and the development of aGVHD. There have been
Figure 2. Serum sBAFF levels during the peritransplantation period according to the development of aGVHD. The dot plot shows that patients with
aGVHD have lower sBAFF levels at all sampling times. Each symbol represents one patient; small horizontal lines indicate the median.
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vival and activation factor [8-10], as well as its associa-
tion with autoimmune diseases [12-15] and cGVHD
[19-21]. Moreover, T cells have been shown to express
BAFF receptors [39], and several studies have demon-
strated that sBAFF promotes T cell activation and sur-
vival [40]. But, despite these effects of sBAFF on T
cells, which perform a pivotal role in the pathogenesis
of aGVHD [7], to date no study has evaluated the as-
sociation between sBAFF and aGVHD. Our findings
suggest that high sBAFF levels during the peritrans-
plantation period may confer protection against the
development of aGVHD, in contrast to previous re-
ports of a correlation between high sBAFF level and
the occurrence of cGVHD [19-21].
Several previous in vitro studies have verified the
role of sBAFF as a costimulatory/survival factor for ac-
tivated T cells [25-27]. The physiological importance
of sBAFF function in T cells in vivo remains to be
clearly elucidated, however. Indeed, observations that
BAFF-deficient mice have normal T cell numbers
and immune responses, including allograft rejection,
suggest that BAFF per se is not required for T cell
function [10,27,39]. Although the proportion of effec-
tor T cells was increased in BAFF-transgenic (Tg)
mice, these mice were protected against ovalbumin-
induced allergic airway inflammation, whereas de-
layed-type hypersensitivity responses were enhanced
and prolonged, suggesting a possible regulatory role
for sBAFF in T cell activation in some settings [27].
Other evidence suggesting a regulatory role for sBAFF
in T cell activation are the findings that sBAFF can
induce an increase in CD25 expression on activated
T cells [25] and that BAFF receptors are expressedon the majority of CD251 regulatory T cells [39]. In-
direct effects, such as the sBAFF-mediated production
of interleukin-10 by B cells, also may play a role in the
negative regulation of certain aspects of T cell function
[41]. Taken together, these findings demonstrate that
sBAFF has a complex, dichotomous role in immunity
mediated by the differential regulation of T cell– and
B cell–dependent immune responses [28].
Given our current level of knowledge, a number of
caveats call into question the actual role of sBAFF in
the regulation of T cell–dependent immunity. Inter-
estingly, Walters et al. [28] recently reported pro-
foundly compromised T cell effector responses in
BAFF-Tg mice. They found that sBAFF plays a sur-
prising anti-inflammatory role in T cell biology by
promoting the expansion of CD41CD251Foxp31
regulatory T cells (Tregs), using BAFF-Tg mice that
accepted islet allografts and exhibited delayed rejec-
tion of skin allografts. In the setting of human alloge-
neic SCT, we have demonstrated sBAFF’s potential
protective effect against GVHD during the peritrans-
plantation period, which may be another piece of evi-
dence suggesting the negative regulatory role of
sBAFF in T cell function. The interaction between
sBAFF and Tregs may be a possible mechanism ex-
ploited by sBAFF in the suppression of T cell immu-
nity. The association between sBAFF level and Tregs
after allogeneic SCT merits further investigation in
animal and human studies.
Another possible mechanism for the sBAFF’s
aGVHD-protective role is its ability to regulate T
helper cell (Th) 1 and Th2 responses. Several studies
have demonstrated that dysregulation of Th1 or
Th2 responses may contribute to aGVHD [42-44],
Table 2. sBAFF Levels at Each Time Point According to Transplant Characteristics*
Characteristic n Preconditioning P Day 0 P Day +7 P Day +14 P
Patient age, years .434 .794 .481 .615
# 30 23 38.9 ± 8.8 29.8 ± 5.2 37.3 ± 7.1 40.7 ± 6.4
> 30 22 44.5 ± 8.3 31.3 ± 5.2 28.3 ± 5.0 39.4 ± 8.7
Donor age, years NA NA .311 .990
# 27 24 31.7 ± 6.7 41.7 ± 8.4
> 27 21 34.2 ± 5.4 38.2 ± 6.6
Patient sex .513 .656 .918 .340
Male 25 39.8 ± 8.6 28.7 ± 4.8 32.4 ± 5.8 44.8 ± 7.8
Female 20 43.9 ± 8.6 32.9 ± 5.7 33.4 ± 6.8 33.7 ± 6.9
Donor sex NA NA .375 .513
Male 28 35.9 ± 5.0 39.3 ± 5.2
Female 17 27.8 ± 8.3 41.1 ± 11.1
Sex match NA NA .674 .980
Match 22 36.6 ± 7.7 38.0 ± 6.0
Mismatch 23 29.3 ± 4.5 42.1 ± 9.0
Female to male NA NA .284 .408
Female to male 30 30.2 ± 5.2 39.1 ± 7.4
Other 15 38.1 ± 8.1 42.0 ± 6.7
ABO type NA NA .386 .344
Match 17 38.4 ± 7.5 31.7 ± 5.9
Mismatch 28 29.5 ± 5.4 44.7 ± 7.6
Disease type .571 .978 .525 .689
AML 22 37.9 ± 6.3 31.3 ± 5.5 36.2 ± 6.7 35.5 ± 6.6
ALL 20 48.9 ± 12.1 29.7 ± 5.6 27.6 ± 5.6 44.8 ± 9.7
CML 3 28.3 ± 11.4 30.3 ± 5.7 43.7 ± 26.7 44.7 ± 15.5
Disease status .693 .116 .240 .137
Standard 35 42.9 ± 7.6 27.5 ± 4.1 28.7 ± 4.0 37.1 ± 6.3
Advanced 10 38.2 ± 7.8 41.3 ± 7.6 47.5 ± 13.5 50.8 ± 9.3
Donor type NA NA .146 .056
Sibling 22 26.3 ± 5.2 30.1 ± 6.1
Unrelated 23 39.1 ± 6.8 50.0 ± 8.4
HLA match NA NA .847 .150
Match 37 33.5 ± 5.1 35.3 ± 4.7
Mismatch 8 29.9 ± 7.1 64.0 ± 20.8
Stem cell source NA NA .776 .259
Bone marrow 29 31.8 ± 5.2 33.2 ± 4.8
Peripheral blood 16 34.9 ± 8.2 51.2 ± 11.4
GVHD prophylaxis NA .314 .170 .055
CsA +MTX 20 26.6 ± 5.2 26.2 ± 5.4 27.5 ± 5.0
Tacrolimus + MTX 25 33.7 ± 5.1 38.2 ± 6.5 50.4 ± 8.4
Mononuclear cells† NA NA NA r 5 -0.190 .360 r 5 0.090 .520
CD34+ cells† NA NA NA r 5 0.203 .229 r 5 0.190 .313
CD3+ cells† NA NA NA r 5 -0.071 .681 r 5 0.057 .749
NA indicates not applicable; AML, acute myelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; CsA,
cyclosporine A; GVHD, graft-versus-host disease; MTX, methotrexate.
*Reported as mean 6 standard error of the mean.
†Correlations between infused donor cells and sBAFF levels were analyzed by Spearman analysis.
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aGVHD pathogenesis remains somewhat controver-
sial [45]. The mechanisms underlying the initiation
and maintenance of the polarization of donor T cells
to the Th1 or Th2 phenotypes have yet to be thor-
oughly elucidated, but instructive signals in the form
of cytokines and cell surface molecules expressed by an-
tigen-presenting cells (APCs) are crucial in this regard
[45]. Given that locally and/or systemically distributed
sBAFF has been shown to affect Th1 and Th2
responses and to have an impact on the course of
some T cell–mediated inflammatory reactions [27],
sBAFF may be one of the major cytokines affecting do-
nor T cell subsets, especially early after transplantation.
Thus, considering sBAFF’s ability to regulate Th1 and
Th2 responses and its association with aGVHD in thepresent study, further experimental and clinical studies
addressing the association of sBAFF with Th1/Th2 po-
larization are needed to gain more insight into the path-
ogenesis of aGVHD.
Several previous studies have explored the role of B
cells in the development of aGVHD. Using a mouse
model, Schultz et al. [46] found that B cell–depleted re-
cipients had a lower incidence of GVHD compared
with control mice. In a human study, Iori et al. [23]
found a correlation between B cell concentration in
G-CSF–mobilized stem cell grafts and an increased
incidence of aGVHD in recipients of allogeneic
HLA-identical sibling transplants [23]. Recently,
Ratanatharathorn et al. [22] reported that B cell deple-
tion in the recipient by rituximab (used to treat patients
with B cell lymphoma before SCT) resulted in a lower
Table 3. Transplant Characteristics According to the Occurrence of aGVHD
Characteristics aGVHD (n5 33) No aGVHD (n5 12) P
Patient age, years, mean (SE) 30 (1.7) 29 (3.4) .572
Donor age, years, mean (SE) 28 (1.3) 35 (4.4) .237
Patient sex, male/female, n (%) 20 (61)/13 (39) 5 (42)/7 (58) .258
Donor sex, male/female, n (%) 20 (61)/13 (39) 8 (67)/4 (33) 1.000
Sex match, match/mismatch, n (%) 17 (51)/16 (49) 5 (42)/7 (58) .559
Female to male, yes/no, n (%) 21 (64)/12 (36) 9 (75)/3 (25) .722
ABO type, match/mismatch, n (%) 12 (36)/21 (64) 5 (42)/7 (58) .746
Disease type, n (%) .580
AML 15 (46) 7 (58)
ALL 16 (48) 4 (33)
CML 2 (6) 1 (8)
Disease status, standard/advanced, n (%) 27 (82)/6 (18) 8 (67)/4 (33) .418
Donor type, sibling/unrelated, n (%) 17 (51)/16 (49) 5 (42)/7 (58) .559
HLA match/mismatch, n (%) 29 (88)/4 (12) 8 (67)/4 (33) .181
Stem cell source, bone marrow/peripheral blood, n (%) 22 (67)/11 (33) 7 (58)/5 (42) .606
TBI or non-TBI, TBI/non-TBI, n (%) 31 (94)/2 (6) 9 (75)/3 (25) .109
GVHD prophylaxis, n (%) .502
CsA +MTX 16 (49) 4 (33)
Tacrolimus + MTX 17 (51) 8 (67)
Infused cells, mean (SE)
Mononuclear cells (108/kg) 5.3 (1.2) 5.5 (1.4) .221
CD34+ cells (106/kg) 4.5 (0.6) 5.0 (0.5) .124
CD3+ cells (107/kg) 18.0 (3.5) 19.3 (7.0) .985
SE indicates standard error; AML, acutemyelogenous leukemia; ALL, acute lymphoblastic leukemia; CML, chronic myelogenous leukemia; TBI, total body
irradiation; CsA, cyclosporine A; GVHD, graft-versus-host disease; MTX, methotrexate.
Biol Blood Marrow Transplant 16:629-638, 2010 635BAFF and Acute GVHDincidence of aGVHD, suggesting that an altered B cell
population in recipients can affect the incidence of
aGVHD [22]. In the present study, a higher sBAFF
level at every time point was associated with a lowerFigure 3. ROC curves of serum sBAFF levels at each sampling time, including p
at every time point were available for prediction of development of aGVHD. Aincidence of aGVHD. A higher sBAFF level may re-
flect relative B lymphopenia during the peritransplan-
tation period; previous studies have demonstrated an
inverse correlation between sBAFF levels and thereconditioning (A), day 0 (B), day17 (C), and day114 (D). sBAFF levels
UC, area under the ROC curve.
Figure 4. Cumulative incidence of aGVHD according to groups at each sampling time, including preconditioning (A), day 0 (B), day17 (C), and day114
(D). Patients were divided into 2 groups, high sBAFF (.43 pg/mL) and low sBAFF (#43 pg/mL), by the identical cutoff value determined by ROC curve
analysis, which could ensure 75% sensitivity and 73%-82% specificity for the prediction of aGVHD at every time point. sBAFF level at every time point
plays a significant predictive role for the occurrence of aGVHD.
636 Biol Blood Marrow Transplant 16:629-638, 2010B.-S. Cho et al.number of B cells [19,21]. sBAFF before conditioning
was definitely produced from recipients, which can re-
flect their immunologic status, particularly in terms of
B cell homeostasis, which might be affected by previ-
ous chemotherapy and the status of residual disease.
The altered B cell population may be associated withTable 4. Transplant Characteristics Associated with sBAFF Group
Characteristic n
Pr
P Valu
L
Patient age, years (#30 vs >30) 23 vs 22
Donor age, years (#27 vs >27) 24 vs 21
Patients sex (male vs female) 25 vs 20
Donor sex (male vs female) 28 vs 17
Sex match (match vs mismatch) 22 vs 23
Female to male (female to male vs others) 30 vs 15
ABO type (match vs mismatch) 17 vs 28
Disease type (AML vs ALL vs CML) 22 vs 20 vs 3
Disease status (standard vs advanced) 35 vs 10
Donor type (sibling vs unrelated) 22 vs 23
HLA match (match vs mismatch) 37 vs 8
Stem cell source (bone marrow vs peripheral blood) 29 vs 16
TBI or non-TBI (TBI vs non-TBI) 40 vs 5
GVHD prophylaxis (CsA + MTX vs tacrolimus + MTX) 20 vs 25
Number of infused mononuclear cells NA
Number of infused CD34+ cells NA
Number of infused CD3+ cells NA
NA indicates not applicable; AML, acutemyelogenous leukemia; ALL, acute lymp
irradiation; CsA, cyclosporine A; MTX, methotrexate; sBAFF, soluble B cell ac
*sBAFF levels at every time point were classified as high or low based on a cuchanges in aGVHD incidence, as has been reported
previously [22]. sBAFF levels on day 0 were also pro-
duced from recipients, but can be affected by the con-
ditioning regimen. Sarantopoulos et al. [21] reported
that sBAFF levels on day 0 appeared to be higher in pa-
tients who did not develop cGVHD, in agreementat Each Time Point*
econditioning
e (High, n5 15;
ow, n5 30)
Day 0 P Value
(High, n5 11;
Low, n5 34)
Day +7 P Value
(High, n5 15;
Low, n5 30)
Day +14 P Value
(High, n5 17;
Low, n5 28)
.673 .666 .399 .155
NA NA .526 .565
.396 .438 .671 .114
NA NA .341 .789
NA NA .833 .848
NA NA .502 .384
NA NA .348 .367
1.000 .879 .885 .273
.710 .687 .205 .143
NA NA .140 .153
NA NA .410 .226
NA NA .660 .209
NA .121 .315 .350
NA .729 .118 .113
NA NA .342 .231
NA NA .243 .125
NA NA .591 .780
hoblastic leukemia; CML, chronic myelogenous leukemia; TBI, total body
tivating factor.
toff value of 43 pg/mL.
Biol Blood Marrow Transplant 16:629-638, 2010 637BAFF and Acute GVHDwith our data showing a lower incidence of aGVHD in
patients with a higher sBAFF level on day 0, because
previous aGVHD is a well-known risk factor for sub-
sequent cGVHD [24]. A higher sBAFF level on day
0 may be a precondition for adequate B cell reconstitu-
tion, which is important for the prevention of
cGVHD, as noted by Sarantopoulos et al. [21]. On
the other hand, sBAFF levels on days 17 and 114
were produced from donor cells as well as recipient
cells, complicating further explanations of possible
mechanisms. Take together, our data suggest the
need for further studies exploring the association be-
tween sBAFF levels and B cell numbers during the
peritransplantation period.
Previous reports in the setting of allogeneic SCT
have reported higher sBAFF levels compared with
the levels reported here (ng/mL vs pg/mL) [19-21].
Whereas those previous studies measured sBAFF in
plasma, we measured sBAFF in serum, in the same
manner as Doreau et al. [47] did in patients with sys-
temic lupus erythematosus and healthy controls. Com-
paring the sBAFF levels of healthy controls in the
above-cited studies appears to show that sBAFF levels
measured using the same ELISA kit appear to be
higher in plasma than in serum. The reason for this dif-
ference merits investigation. In addition, directly com-
paring previous data with our data is impossible,
because the previous studies measured sBAFF levels
several months after SCT, whereas our results are de-
rived from the peritransplantation period (within 2
weeks of transplantation).
To the best of our knowledge, this study is the first
to demonstrate an association between high sBAFF
level during the peritransplantation period and a de-
creased incidence of aGVHD in humans. Our under-
standing of the pathogenesis of aGVHD has
improved dramatically, which has led to new modali-
ties of treatment and management; nonetheless, new
insight is needed into the underlying risk factors pre-
dicting the development of aGVHD. Our findings
also demonstrate that sBAFF level during the peri-
transplantation period may be considered a predictor
for aGVHD. Further trials with a larger cohort are
needed to determine a definite cutoff value of high
sBAFF level, as well as to construct an index with pre-
viously known factors for the prediction of aGVHD.
The discovery of useful mechanisms of sBAFF in the
regulation of T cells or B cells holds promise for the
development of new, more effective therapeutic inter-
ventions for aGVHD.ACKNOWLEDGMENTS
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